A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma

Uterine Serous Carcinoma Clinical Trial

Official title:
A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women With Recurrent or Persistent Uterine Serous Carcinoma

Status Recruiting

Clinical Trial Summary

This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).

Clinical Trial Description

This is a Phase 2 open-label, multicenter study to evaluate the clinical activity and safety of ZN-c3 (also known as azenosertib; KP-2638) in adult women with recurrent or persistent uterine serous carcinoma (USC). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04814108
Study type	Interventional
Source	K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Contact	Project Director
Phone	(858) 263-4333
Email	medicalaffairs@zentalis.com
Status	Recruiting
Phase	Phase 2
Start date	July 28, 2021
Completion date	May 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06369155` - Azenosertib in Uterine Serous Carcinoma: Biomarker Study	Phase 2
Recruiting	`NCT05902988` - A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer	Phase 1/Phase 2
Completed	`NCT04590248` - A Study of Adavosertib as Treatment for Uterine Serous Carcinoma	Phase 2
Recruiting	`NCT04080284` - Trial of Maintenance With Niraparib- Uterine Serous Carcinoma	Phase 2